Claims
- 1. A compound of the formula
- 2. The compound of claim 1, wherein E comprises a pi bond coupled to one N.
- 3. The compound of claim 1, wherein ring A is saturated.
- 4. The compound of claim 1, wherein k is 0-1.
- 5. The compound of claim 4, wherein the ring system which includes A is tetrahydroquinoline or a substituted form thereof.
- 6. The compound of claim 1, wherein one of (CR2)an and (CR2)bn is CH2 and the other is a bond.
- 7. The compound of claim 6, wherein (CR2)an is a bond and (CR2)b is CH2.
- 8. The compound of claim 7, wherein the ring system that includes A is tetrahydroquinoline or a substituted form thereof.
- 9. The compound of claim 8, wherein ring E comprises a pi bond coupled to one N.
- 10. The compound of claim 9, wherein W is a 5-6 membered heterocyclic ring optionally substituted with (CR2)m—NH2 where m=0-1, benzyl or halo.
- 11. The compound of claim 10, wherein W is pyridyl, oxazolyl or imidazolyl.
- 12. The compound of claim 9, wherein W is of the formula
- 13. The compound of claim 12, wherein Z1 and Z2 are independently N or O.
- 14. The compound of claim 11, wherein at least one Y is —(CR2)m—NH2, where m=0−1, benzyl or halo.
- 15. The compound of claim 11, wherein said compound is selected from the group consisting of
(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-[(1-aminomethyl)-benzoxazol-3-ylmethyl)]-amine; (1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-[(1-benzyl-2-aminomethyl)-imidazol-5-ylmethyl)]-amine; 6-aminomethylpyridin-3-ylmethyl-(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amine; (6-aminopyridin-3-ylmethyl)-(benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amine; (2-aminopyridin-3-ylmethyl)-(benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-8-quinolinyl)-amine; (6-amino-pyridin-2-ylmethyl)-(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine; (4-amino-pyridin-3-ylmethyl)-(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine; (1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-(imidazol-2-yl)-methylamine; 4-{[(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amino]-methyl}-2,6-diichloropyridine; (1H-benzimidazol-2-ylmethyl)-benzooxazol-5-ylmethyl-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine; pyridin-2-ylmethyl-(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydroquinolin-8-yl)-amine; (1H-benzimidazol-2-ylmethyl)-benzoxazol-6-ylmethyl-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine; (1H-benzimidazol-4-ylmethyl)-(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine; (1H-benzimidazol-2-ylmethyl)-pyridin-4-ylmethyl-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine; (1H-benzimidazol-2-ylmethyl)-(benzo [1,3]dioxol-4-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine; benzo[1,3]dioxol-5-ylmethyl-(1H-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine; (1H-benzimidazol-2-ylmethyl)-(2,3-dihydro-benzofuran-7-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine; (1H-benzimidazol-2-ylmethyl)-pyridin-3-ylmethyl-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine; (1H-benzoimidazol-5-ylmethyl)-(1H-benzoimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine; bis-(1H-benzimidazol-2-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine; (1H-benzimidazol-2-ylmethyl)-(3H-imidazol-4-ylmethyl)-(5,6,7,8-tetrahydro-quinolin-8-yl)-amine; or a salt thereof.
- 16. A pharmaceutical composition for modulating chemokine receptor activity comprising a therapeutically effective amount of the compound of claim 11.
- 17. The pharmaceutical composition of claim 16, wherein (CR2)an is a bond and (CR2)bn is CH2.
- 18. The pharmaceutical composition of claim 17, wherein the ring system that includes A is tetrahydroquinoline or a substituted form thereof.
- 19. The pharmaceutical composition of claim 18, wherein ring E comprises a pi bond coupled to one N.
- 20. A pharmaceutical composition for modulating chemokine receptor activity comprising a therapeutically effective amount of the compound of claim 15.
- 21. A method to treat HIV or FIV, comprising administering to a subject in need of such treatment an effective amount of the compound of any of claim 1, or a pharmaceutical composition thereof.
Parent Case Info
[0001] This application is a continuation of U.S. patent application Ser. No. 10/031,812, allowed, which claims priority under 35 U.S.C. 119(e) from Provisional Application 60/232,891 filed 15 Sep. 2000; 60/234,510 filed 22 Sep. 2000; application Ser. No. 0/233,087 filed 15 Sep. 2000; and application Ser. No. 60/234,816 filed 22 Sep. 2000. The contents of these applications are incorporated herein by reference.
Continuations (1)
|
Number |
Date |
Country |
Parent |
10031812 |
Mar 2002 |
US |
Child |
10799386 |
Mar 2004 |
US |